Tarsus Pharmaceuticals (TARS)

• Market cap: $2.57B
• 1 day: -1.95%
• 5 days: 2.97%
• 1 month: -3.77%
• 3 months: -5.06%
• 6 months: -8.15%
• Year to date: -27.01%
• 1 year: 41.2%
• 5 years: 148.94%
• 10 years: 186.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Employees: 370